In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition.

J Exp Clin Cancer Res · 2025 · PMC12255093 · PMID 40652269

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

of borderline significancep = 0.058so close (0.05 < p ≤ 0.1)

Patients with detectable ctDNA showed a trend of borderline significance towards a shorter PFS (median PFS: 4 months [95% CI: 3–16] vs. 12 months [95% CI: 9- NA]) than patients without detectable ctDNA ( p = 0.058) (Suppl.

also in 361 other papers

showed a trendp = 0.058so close (0.05 < p ≤ 0.1)

Patients with detectable ctDNA showed a trend of borderline significance towards a shorter PFS (median PFS: 4 months [95% CI: 3–16] vs. 12 months [95% CI: 9- NA]) than patients without detectable ctDNA ( p = 0.058) (Suppl.

also in 17,257 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.